Archives
|
Entry
|
Blogger
|
Date
|
Location
|
|
Infinity’s New CEO, Veteran Dealmaker, Seeks to Deliver on Company’s Early Promise
|
Luke Timmerman |
02/09/10 |
Boston
|
|
Tragara Raises $5M
|
Bruce V. Bigelow |
02/08/10 |
San Diego
|
|
Cell Therapeutics Shares Fall as FDA Says Lymphoma Drug Has “Substantial” Side Effects
|
Luke Timmerman |
02/08/10 |
Seattle
|
|
Carl Icahn Nominates Scripps Researcher to Biogen Idec Board, BrainCells Pursues New Drug Combo for Depression, Illumina Adds to Oxford Nanopore Investment, & More San Diego Life Sciences News
|
Bruce V. Bigelow |
02/04/10 |
San Diego
|
|
Cell Therapeutics Nears Judgment Day, AVI Biopharma Awaits Results, HemaQuest Gets $6M & More Seattle-Area Life Sciences News
|
Luke Timmerman |
02/04/10 |
Seattle
|
|
$9M for Syndax Pharmaceuticals
|
Erin Kutz |
02/03/10 |
Boston
|
|
Seattle Genetics Starts Lymphoma Trial
|
Luke Timmerman |
02/03/10 |
Seattle
|
|
Cell Therapeutics FDA Panel Primer: What You Need to Know to Be Ready Next Week
|
Luke Timmerman |
02/03/10 |
Seattle
|
|
Hemaquest Snaps Up $6M To Treat Sickle Cell, Other Blood Disorders
|
Luke Timmerman |
02/01/10 |
Seattle
|
|
UW Honors Medical Device Entrepreneur Joe Eichinger For 35 Years Of Service
|
Thea Chard |
01/29/10 |
Seattle
|
|
A Contract Services Cluster Emerges, the Burnham Gets a Big Donation, Somaxon Resubmits Sleep Drug Application, & More San Diego Life Sciences News
|
Denise Gellene |
01/28/10 |
San Diego
|
|
Prometheus Positions for IPO, Licenses Novartis Drug
|
Bruce V. Bigelow |
01/26/10 |
San Diego
|
|
Millennium, In a New Role, Flexes Global Muscle to Cut Deal With Seattle Genetics
|
Ryan McBride |
01/26/10 |
Boston
|
|
San Diego’s Halozyme Injects New Life into Old Drugs
|
Denise Gellene |
01/26/10 |
San Diego
|
|
6 Goals for Fixing Genzyme: Xconomy’s Q&A With Relational Investors’ Ralph Whitworth
|
Bruce V. Bigelow |
01/21/10 |
San Diego
|
|
Dendreon’s New Operations Man, Acucela Enters Fast Growth Phase, JP Morgan Recap, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
01/21/10 |
Seattle
|
|
Roche Prepares to Make Devices for Drug Using Halozyme Therapeutics Technology
|
Denise Gellene |
01/21/10 |
San Diego
|
|
Quanterix CEO Sets Sight on Early Detection of Cancer, Neurological Diseases in the Blood
|
Luke Timmerman |
01/19/10 |
Boston
|
|
Dendreon’s New Operations Man, Hans Bishop, Aims to Keep Provenge Trains Running on Time
|
Luke Timmerman |
01/19/10 |
Seattle
|
|
Genomic Advances of the 2000s Will Demand an Informatics Revolution in the 2010s
|
Eric Schadt |
01/14/10 |
National
|
|
Once Destined for Bankruptcy, Adventrx Pharmaceuticals Sets New Course With Reformulated Drugs
|
Bruce V. Bigelow |
01/13/10 |
San Diego
|
|
DataSphere and Halosource Get Funded, Sage Signs Up Pfizer, Zymo Raises $90M, & More Seattle-Area Deals News
|
Gregory T. Huang |
01/12/10 |
Seattle
|
|
VentiRx Nabs $25M for Cancer, Allergy Drugs
|
Luke Timmerman |
01/12/10 |
San Diego
|
|
Sage Bionetworks Strikes Deal With Pfizer to Find Cancer Drug Targets
|
Luke Timmerman |
01/11/10 |
Seattle
|
|
Synta Nabs $25M in Stock Deal
|
Luke Timmerman |
01/08/10 |
Boston
|
|
Five Disruptive Biotech Ideas to Watch in the Coming Decade
|
David Walt |
01/08/10 |
Boston
|
|
Alder Rises from Ashes, Seattle Genetics Gets Empowered, ZymoGenetics Nets $79M & More Seattle-Area Life Sciences News
|
Luke Timmerman |
01/07/10 |
Seattle
|
|
Predictive Buys OncoDiagnostic Lab
|
Luke Timmerman |
01/07/10 |
Boston
|
|
Biogen Idec CEO Stepping Down, Ambrx Focuses on Empowered Antibodies, Intellikine Testing First Drug Candidate, & More San Diego Life Sciences News
|
Bruce V. Bigelow |
01/07/10 |
San Diego
|
|
Seattle Genetics Maps Out a Future With Antibody Drugs That Are “Empowered”
|
Luke Timmerman |
01/06/10 |
Seattle
|
|
Page 1 of
18 |
next page » |
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.
© 2007-2009, Xconomy, Inc.
XCONOMY is a registered service mark of Xconomy, Inc.
All rights reserved.
Site designed by
Matthew Bouchard, produced by
Andrew Koyfman,
and powered by WordPress.
